Pharmacology
-
Brensocatib awaits FDA approval for bronchiectasis following ASPEN results
Experts Mark Metersky, MD, FCCP; Pamela J. McShane, MD; and Charles L. Daley, MD, FCCP, discuss the potential clinical implications of addressing inflammation in bronchiectasis—from reduced exacerbations and slowed decline in FEV to improved quality of life.
-
MATINEE shows positive results for mepolizumab in COPD
Experts Frank Sciurba, MD, FCCP, and Gerard J. Criner, MD, FCCP, said clinicians have a second option for treating patients with high type 2 inflammation now that the FDA has approved the drug for those with an eosinophilic phenotype.
-
Study to test efficacy of tezepelumab for treating asthma exacerbations in the emergency department
Diego J. Maselli, MD, FCCP, said the TERAA trial will provide needed evidence on the use of biologics in the acute care setting.
-
Pooled data suggest sotatercept as novel disease-modifying therapy for PAH
Aaron B. Waxman, MD, PhD, FCCP, said he believes the drug will become a first-line therapy option, but questions remain regarding when to initiate treatment.
-
Top-line results from FIBRONEER-ILD point to possible third agent for interstitial lung disease
If the data prove accurate, Barry Shea, MD, said nerandomilast could become the first new treatment for lung fibrosis in more than a decade.
-
Tezepelumab trial demonstrates solid results for treatment of CRSwNP
Joseph K. Han, MD, said the data showed the highest change in sinonasal outcome test scores from baseline compared with any other biologic studies for chronic rhinosinusitis with nasal polyps.
-
Delving deeper into the molecular genetics of idiopathic pulmonary fibrosis
William Whalen II, MD, MS, reflects on his experience as a recipient of the 2023 CHEST Research Grant in Pulmonary Fibrosis and how it has affected his professional trajectory.
-
COPD: Could there be a GLP-1 for that?
While real-world data are promising, experts Dinah Foer, MD, and William B. Feldman, MD, say more randomized controlled trials are needed to confirm whether antihyperglycemic medications can improve respiratory outcomes in patients with comorbid type 2 diabetes and COPD.
-
TETON trials could herald multimodal approach to IPF
Steven Nathan, MD, said the addition of inhaled treprostinil would offer a novel approach that would allow clinicians to target the disease on two fronts.
-
Parkinson’s drug shows promise as treatment for nicotine addiction in mouse model
Tobacco cessation expert, Carolyn Dresler, MD, MPA, said new evidence of cross talk between different types of acetylcholinergic receptors could be an important step for future research to determine if, and at what doses, these results could be replicated in humans.